B2C Bio


B2C Bio is a small biotechnology company focused on translating bionanotechnology into diagnostic and therapeutic solutions. The organization develops point-of-care multiplex diagnostics, nasal delivery platforms for CNS targeting using bionanomaterials, and rapid exosome isolation/purification methods. Leadership combines clinical and chemistry expertise supporting translational research and academic collaborations.

Industries

biotechnology
clinical-trials
pharmaceutical

Nr. of Employees

small (1-50)

B2C Bio

Aurora, Colorado, United States, North America


Products

Point-of-care multiplex diagnostic platform

A diagnostic system for near-patient testing designed for minimal sample preparation, multiplexed detection, and high sensitivity for applications such as early cancer screening and therapeutic drug monitoring.

Nasal CNS delivery platform

A delivery platform combining bionanomaterials and a device to facilitate intranasal administration intended to improve CNS delivery of molecules that do not readily cross the blood–brain barrier.

Rapid exosome isolation and purification method

A method under development to quickly isolate and purify exosomes for research and potential clinical use.

Expertise Areas

  • Translational research (bench-to-clinic)
  • Point-of-care diagnostics and assay development
  • Nanomaterials for drug delivery
  • Exosome isolation and characterization
  • Show More (4)

Key Technologies

  • Bionanomaterials
  • Intranasal (nasal) delivery devices for CNS targeting
  • Point-of-care multiplex molecular diagnostics
  • Rapid exosome isolation and purification methods
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.